Trial Radar
Sign in

NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Letermovir for R+ Study
Letermovir for R+ Study

NCT07706166

Not Yet RecruitingPhase 4

Sponsor: University of Wisconsin, Madison

Conditions: Kidney Transplant, Liver Transplant

Interventions: Letermovir

Countries: United States

The purpose of this clinical trial is to find out whether a medication, called letermovir, can help prevent a virus called cytomegalovirus (CMV) in participants who receive a kidney or liver transplant and who have already been exposed the CMV. Participants will take letermovir for 84 days.

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria
Inclusion Criteria:

* Adults who are at moderate risk for CMV after transplant (CMV IGG+, including D+/R+ or D-/R+)
* Adults who received a kidney transplant, liver transplant, or any combination thereof

Exclusion Criteria:

* Known contraindication to letermovir or its excipients
* Current participation in another CMV related study
* Unwilling or unable to participate in the study protocol
Locations (1)
  • Madison, Wisconsin, United States